Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleAccepted Article
Open Access

Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs

Glen S Hazlewood, Jordi Pardo Pardo, Cheryl Barnabe, Orit Schieir, Claire E.H. Barber, Laurie Proulx, Dawn P. Richards, Peter Tugwell, Nick Bansback, Pooneh Akhavan, Claire Bombardier, Vivian Bykerk, Shahin Jamal, Majed Khraishi, Regina Taylor-Gjevre, Carter Thorne, Arnav Agarwal and Janet E Pope
The Journal of Rheumatology July 2022, jrheum.220209; DOI: https://doi.org/10.3899/jrheum.220209
Glen S Hazlewood
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Pardo Pardo
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Barnabe
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orit Schieir
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire E.H. Barber
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurie Proulx
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn P. Richards
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Tugwell
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Bansback
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pooneh Akhavan
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Bombardier
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivian Bykerk
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahin Jamal
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Majed Khraishi
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regina Taylor-Gjevre
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carter Thorne
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arnav Agarwal
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet E Pope
Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada; Arthritis Research Canada, Vancouver, BC, Canada; Cochrane Musculoskeletal, University of Ottawa, Ottawa, Ontario, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Department of Medicine and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada; School of Population and Public Health, University of British Columbia, Vancouver, Canada; Division of Rheumatology, Mount Sinai Hospital, Toronto, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Hospital for Special Surgery, New York, New York; Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Department of Medicine, Memorial University of Newfoundland, St. Johns, Newfoundland and Labrador, Canada; Division of Rheumatology, Department of Medicine, College of Medicine, University of Saskatchewan; The Centre of Arthritis Excellence and The Arthritis Program Research Group, Newmarket, ON; Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario; Dept of Medicine, Western University, Schulich School of Medicine & Dentistry, London, Ontario. Funding: Funding for this guideline was provided by the Canadian Rheumatology Association. Conflicts of interest: G Hazlewood: None; J Pardo: Funding from Canadian Rheumatology Association to Cochrane Musculoskeletal to provide methodological support for guideline development. C Barnabe: Honoraria for advisory boards (Gilead, Sanofi, Celltrion) and speaker fees (Sanofi) in past 3 years; O Schieir: None; C Barber: None; L Proulx: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. LP has received payment and travel support in the last 3 years from Lilly Canada (sharing patient perspectives at an event); D. Richards: Volunteer Vice President of Canadian Arthritis Patient Alliance which receives the majority of its funding from independent grants from pharmaceutical companies. DR's employer, Five02 Labs Inc, has received payment in the last 3 years from Novo Nordisk Canada (speaking on living with arthritis and arthritis advocacy) and Lilly Canada (sharing patient story, participating in an advisory board); P Tugwell: None; N Bansback: None; P Akhavan: Honoraria for advisory boards (Janssen, Eli Lilly, Pfizer, Sandoz, Celltrion, AbbVie, Roche); C Bombardier: Consulting for Novartis, Samsung. Honoraria for AbbVie, Janssen, Merck, Pfizer, GSK, Mylan; V Bykerk: Consultant: Amgen, BMS, Gilead, Genzyme, Regeneron, UCB; Research funding: Amgen, BMS, Genzyme, Pfizer, Sanofi Aventis, UCB; S Jamal: Honoraria for advisory boards (Abbvie, Amgen, BMS, Boehringer, Celgene, Celltrion, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, Teva, UCB); M Khraishi: Consulting for Amgen, Abbvie, Celgene, Merck, Novartis, Pfizer, Gilead; R Taylor-Gjevre: None; C Thorne: Consulting for Celgene, AbbVie, Merck, Pfizer, Sandoz; A Agarwal: None; JE Pope: Consulting for AbbVie, Amgen, BI, BMS, Celltrion, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, Medexus, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sanofi, Sobi, Teva, UCB, VIatris. Correspondence to: Glen S Hazlewood, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, T2N 4Z6, Canada. E-mail: gshazlew@ucalgary.ca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Data supplements

  • Data Supplement

    • 220209DataSuppl.pdf
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs
Glen S Hazlewood, Jordi Pardo Pardo, Cheryl Barnabe, Orit Schieir, Claire E.H. Barber, Laurie Proulx, Dawn P. Richards, Peter Tugwell, Nick Bansback, Pooneh Akhavan, Claire Bombardier, Vivian Bykerk, Shahin Jamal, Majed Khraishi, Regina Taylor-Gjevre, Carter Thorne, Arnav Agarwal, Janet E Pope
The Journal of Rheumatology Jul 2022, jrheum.220209; DOI: 10.3899/jrheum.220209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs
Glen S Hazlewood, Jordi Pardo Pardo, Cheryl Barnabe, Orit Schieir, Claire E.H. Barber, Laurie Proulx, Dawn P. Richards, Peter Tugwell, Nick Bansback, Pooneh Akhavan, Claire Bombardier, Vivian Bykerk, Shahin Jamal, Majed Khraishi, Regina Taylor-Gjevre, Carter Thorne, Arnav Agarwal, Janet E Pope
The Journal of Rheumatology Jul 2022, jrheum.220209; DOI: 10.3899/jrheum.220209
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire